REGENXBIO Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Published: Sep 23, 2015
ROCKVILLE, Md., Sept. 22, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the closing of its initial public offering of 7,245,000 shares of common stock at a public offering price of $22.00 per share, which includes 945,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the initial public offering to REGENXBIO were approximately $159.4 million, before underwriting discounts and estimated offering expenses.
Morgan Stanley and BofA Merrill Lynch acted as active joint book-running managers of the proposed offering. Piper Jaffray acted as a passive book-running manager. Chardan Capital Markets acted as a co-manager.
The offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department; or from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by email at email@example.com.
A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on September 16, 2015. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. REGENXBIO's NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, including five internally developed candidates and 18 partnered candidates developed by REGENXBIO's licensees.
CONTACT: Investors Elizabeth Broder, 646-378-2945 firstname.lastname@example.org Media Laura Bagby, 312-448-8098 email@example.com
Help employers find you! Check out all the jobs and post your resume.